Biogen Accused Of ‘Paying’ PBMs To ‘Manipulate’ US Generic Tecfidera Market
Health Fund Class Action Lawsuit Alleges Unlawful, Anticompetitive Agreements
Spooked by the prospect of earlier-than-expected US generic competition to its powerhouse MS brand Tecfidera, Biogen entered into illicit agreements with PBMs to stifle generic competition while it “scrambled” to switch the market to its follow-on brand, a US class action lawsuit alleges.
